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Synopsis  12 
Background. Imipenem resistance in Pseudomonas aeruginosa most often entails 13 
loss of the ‘carbapenem-specific’ porin OprD; more rarely it reflects acquired 14 
carbapenemases. Loss of OprD only confers resistance to imipenem if AmpC β-15 
lactamase is expressed, and we investigated whether this mechanism was 16 
overcome by relebactam, a developmental diazabicyclooctane -lactamase inhibitor. 17 
Methods. Consecutive P. aeruginosa isolates causing bacteraemia or hospital-onset 18 
lower respiratory tract infections were collected between 2014 and 2016 under the 19 
aegis of the BSAC Resistance Surveillance Programme. Imipenem MICs were 20 
determined centrally by BSAC agar dilution, with relebactam at a fixed concentration 21 
(4 mg/L).  22 
Results. For most imipenem-susceptible P. aeruginosa (726/759, 95.6%) the MICs 23 
of imipenem alone were 0.5-2 mg/L and were decreased 3- to 4-fold by addition of 24 
relebactam, as based on geometric means or modes.  For most imipenem-non-25 
susceptible P. aeruginosa (82/92, 89%), imipenem MICs were 8-16 mg/L, and were 26 
reduced to 1-2 mg/L by relebactam. These patterns applied regardless of whether 27 
the isolates were susceptible to penicillins and cephalosporins or had phenotypes 28 
suggesting derepressed AmpC or upregulated efflux.  Imipenem MICs for five P. 29 
aeruginosa with MBLs remained high (≥16 mg/L) regardless of relebactam.  30 
Conclusions. Potentiation of imipenem by relebactam was almost universal, 31 
according with the view that endogenous pseudomonal AmpC ordinarily protects 32 
against this carbapenem to a small degree. Imipenem MICs were reduced to the 33 
current breakpoint, or lower, except for MBL-producers. Potentiation was not 34 
compromised by derepression of AmpC or upregulation of efflux. 35 
36 
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Introduction 37 
Pseudomonas aeruginosa is the third-most frequent Gram-negative agent of 38 
bacteraemia, with 8.1 reports/100000 population for England, Wales and Northern 39 
Ireland,1 and with this rate increasing by around 16% since 2009.1  P. aeruginosa is 40 
also among the most prevalent agents of hospital-acquired and ventilator-associated 41 
pneumonia, accounting for up to a quarter of cases.2  42 
 As a species, P. aeruginosa is less susceptible than Enterobacteriaceae to 43 
most antibiotics3 reflecting inherent impermeability and efflux-based mechanisms.  44 
Moreover, it can readily mutate to become resistant to those -lactams, 45 
fluoroquinolones and aminoglycosides that ordinarily are active. In the case of 46 
imipenem, mutational resistance almost always arises via functional loss of OprD, a 47 
‘carbapenem-specific’ porin.4  This ‘impermeability-mediated resistance’ requires 48 
continued inducible or derepressed expression of the endogenous AmpC β-49 
lactamase,5 which has a feeble activity against imipenem that becomes significantly 50 
protective once entry of the drug is restricted by porin loss. The involvement of 51 
AmpC is demonstrated by imipenem MICs being reduced if the AmpC enzyme is lost 52 
by mutation5 or is inactivated with penems (e.g. BRL42715)6 or bridged 53 
monobactams (e.g. Ro 48-1256).7 54 
 Relebactam (MK-7655, Merck) is a diazabicyclooctane β-lactamase inhibitor,8 55 
being developed in combination with imipenem.  The combination’s spectrum 56 
includes Enterobacteriaceae with KPC carbapenemases and combinations of AmpC 57 
-lactamase and impermeability as well as P. aeruginosa.9, 10 Using isolates 58 
submitted to the BSAC Resistance Surveillance Programme,11 we examined its 59 
activity against P. aeruginosa isolates in relation to their phenotypic resistance to 60 
imipenem and other agents. 61 
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Materials and methods 62 
Consecutive P. aeruginosa isolates causing bacteraemia and hospital-onset lower 63 
respiratory tract infection (HO-LRTI) were submitted to the BSAC Resistance 64 
Surveillance Programme from sentinel laboratories in the UK and Ireland (see 65 
http://www.bsacsurv.org). Bloodstream isolates were collected from Jan 2015 to Dec 66 
2015 and HO-LRTI isolates from Oct 2014 to Sept 2016.  Thirty-eight laboratories 67 
participated in the first 12-month period, collecting seven isolates per infection type, 68 
whereas 24 laboratories participated in the latter 12-month period, collecting 10 69 
isolates per infection type.  HO-LRTIs were defined as arising >48 h after hospital 70 
admission. Respiratory isolates from cystic fibrosis patients were excluded, as were 71 
repeat isolates from the same patient within 14 days. 72 
Isolates were re-identified centrally by MALDI-TOF and BSAC agar dilution 73 
was used to determine MICs,12 with relebactam combined with imipenem at a fixed 74 
concentration of 4 mg/L. Breakpoints followed EUCAST criteria (v9.0, 2019)13 and it 75 
was assumed that imipenem/relebactam breakpoints would broadly follow those of 76 
imipenem (S ≤4 mg/L, R >4 mg/L for P. aeruginosa).  77 
Isolates were categorised according to their susceptibility to 78 
piperacillin/tazobactam 16 mg/L, ceftazidime 8 mg/L and carbenicillin 128 mg/L; 79 
these values correspond to EUCAST breakpoints for the first two agents,13 whilst the 80 
value for carbenicillin corresponds to the BSAC legacy breakpoint;14 more 81 
importantly all three values correspond to ECOFFS.15  Isolates susceptible to all 82 
three agents on these criteria were categorised as ‘wild-type’; those non-susceptible 83 
to either or both of ceftazidime and piperacillin but susceptible to carbencillin were 84 
categorised as likely AmpC derepressed and those with carbenicillin resistance and 85 
proportionate rises in ceftazidime and piperacillin/tazobactam MICs (irrespective of 86 
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whether or not these conferred non-susceptibility) were categorised as having 87 
upregulated efflux.  The principles of this interpretive reading were outlined 88 
previously,16 although the present analysis was constrained by a limited range of 89 
antibiotics.  These wild type, AmpC-derepressed and upregulated efflux groups, also 90 
a final cluster of unclassifiable isolates, were then categorised as imipenem-91 
susceptible (MIC ≤4 mg/L) and or imipenem non-susceptible (MIC >8 mg/L).  Lastly, 92 
isolates with broad resistance to all -lactams and with ceftazidime MIC >128 mg/L 93 
or imipenem >64 mg/L were subjected to PCR for carbapenemase (blaIMP, blaNDM 94 
and blaVIM)17 and ESBL (blaVEB18 and blaPER19) genes. 95 
Results  96 
In total, 851 P. aeruginosa isolates were tested; 433 from bacteraemia and 418 from 97 
HO-LRTI. MIC distributions of imipenem alone and with relebactam for this entire 98 
collection are depicted in Figure 1, which shows that addition of relebactam reduced 99 
imipenem MICs for almost all isolates.  To better understand this behaviour, we 100 
divided the collection based on their resistance phenotypes to agents other than 101 
imipenem itself, using the interpretive reading principles outlined previously.16  102 
 Most (706/851, 83%) isolates were susceptible to all of 103 
piperacillin/tazobactam, ceftazidime and carbenicillin, both in relation to breakpoints 104 
and to ECOFFs: 669 of these 706 wild-type isolates were susceptible also to 105 
imipenem, whereas 37 were non-susceptible, implying OprD loss in isolation (Table 106 
1).  Twenty-two isolates had profiles suggesting de-repression of AmpC, with non-107 
susceptibility to either or (mostly) both of piperacillin/tazobactam and ceftazidime but 108 
retained susceptibility to carbenicillin 128 mg/L: 13 of these were susceptible to 109 
imipenem 4 mg/L and nine were non-susceptible, implying OprD loss (Table 1). 110 
Next, 102 isolates had non-susceptibility to carbenicillin 128 mg/L, without evidence 111 
†Members are listed in the Acknowledgements section 
of ESBL or MBL activity, and with broadly proportionate rises in ceftazidime and 112 
piperacillin/tazobactam MICs, implying upregulated efflux: 73 of these remained 113 
susceptible to imipenem 4 mg/L whereas 29 were non-susceptible (Table 1), 114 
implying that they also lacked functional OprD. Two highly carbenicillin-resistant 115 
isolates were identified, by PCR, as having ESBLs (1 PER, 1 VEB) and five had 116 
MBLs (4 VIM and 1 NDM); all of these seven were non-susceptible to imipenem 117 
(Table 1).  Finally, after defining these groups, we were left with 14 isolates, all 118 
carbenicillin resistant, that had anomalous profiles, mostly with disproportionately 119 
high resistance to ceftazidime relative to carbenicillin or with high-level resistance to 120 
carbenicillin and piperacillin/tazobactam, but not ceftazidime (Table 1); 4 were 121 
imipenem susceptible and 10 were resistant.  These isolates may have mixed, or 122 
unsuspected resistance mechanisms. 123 
 Modal MICs of all agents for all groups are shown in Table 1, along with 124 
ranges and geometric means for imipenem and imipenem/relebactam only. Addition 125 
of relebactam 4 mg/L typically reduced the MIC of imipenem by around 3-fold (based 126 
on geometric means) or 4-fold (based on modes) for isolates in the imipenem-127 
susceptible groups, from around 1 mg/L to 0.25 mg/L.  MIC reduction for imipenem-128 
resistant groups, excepting the carbapenemase producers, were larger, typically 129 
from 16 mg/L to around 1 -2 mg/L, based on modes, and 7- to 14-fold, based on 130 
geometric means.    131 
 No synergy was seen between imipenem and relebactam for the five MBL 132 
producers, where imipenem MICs remained almost equally high when relebactam 133 
was present (geometric mean 64 mg/L) or absent (geometric mean 55.7 mg/L). 134 
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Discussion 135 
Potentiation of imipenem by relebactam was almost universal for P. aeruginosa, 136 
supporting the view that endogenous AmpC, whether inducible or de-repressed, 137 
protects against the action of imipenem for this species to some degree.5 Addition of 138 
relebactam to imipenem typically resulted in a 3- to 4-fold reduction of imipenem MIC 139 
for imipenem-susceptible P. aeruginosa, regardless of their other resistance, and an 140 
8- to 16-fold reduction for imipenem-non-susceptible P. aeruginosa lacking MBLs. 141 
Relebactam 4 mg/L brought imipenem MICs to the EUCAST breakpoint (4 mg/L), or 142 
below, for 87/92 (95%) imipenem-non-susceptible P. aeruginosa, the exceptions 143 
being the five MBL producers.  Continued potentiation against carbenicillin-resistant 144 
isolates, inferred to have up-regulated efflux, is notable insofar as it implies that this 145 
trait does not impede periplasmic accumulation of sufficient relebactam to inhibit 146 
AmpC activity. Also interesting, albeit based on just two isolates, is the activity of 147 
imipenem/relebactam, at 2-4 mg/L, against the isolates with ESBLs.  ESBL-148 
producing P. aeruginosa, mostly with VEB enzymes (as in one of the present two) 149 
are increasingly seen in the UK.20  Many are imports but PHE is aware of at least 150 
one UK-based outbreak. Most of these ESBL-positive P. aeruginosa are also (as 151 
here) resistant to carbapenems, presumably owing to OprD loss, and are highly 152 
resistant to all other -lactams, including ceftolozane/tazobactam16 and (usually) 153 
ceftazidime/avibactam.20  They present treatment challenges as great as for 154 
carbapenemase producers. The continued resistance of MBL-producing P. 155 
aeruginosa to imipenem/relebactam is predictable; MBLs are not inhibited by 156 
relebactam or other diazabicyclooctane -lactamase inhibitors.10  157 
While the work presented here represents P. aeruginosa isolated from the UK 158 
and Ireland only, our findings corroborate with those of a European study: P. 159 
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aeruginosa isolates (n=1705) collected from intra-abdominal, urinary tract, and lower 160 
respiratory tract infections from patients from 17 European countries, including three 161 
laboratories (n=121 isolates) from the UK. This surveillance found that, whereas 162 
72% (1228/1705) of isolates were susceptible to unprotected imipenem, this 163 
proportion rose to 94.7% (1615/1705) for imipenem/relebactam, with 81% (387/477) 164 
of the imipenem-non-susceptible isolates were rendered susceptible.21 Similar 165 
surveillance of P. aeruginosa isolates (n=845) from patients located across 21 US 166 
found that 70.3% (594/845) were susceptible to imipenem whereas 94.2% (796/845) 167 
were susceptible to imipenem/relebactam. Of the imipenem-non-susceptible isolates, 168 
80.5% (202/251) were rendered susceptible by the addition of relebactam.22  169 
A limitation of our studies is that the isolates were only categorised in terms of 170 
phenotype and not (except for the few ESBL and carbapenemase producers) 171 
genotype.  Diversity may exist among the up-regulated efflux group in terms of (i) the 172 
particular pumps affected,23 (ii) whether pump expression or specificity is altered, 173 
and (iii) whether up-regulation reflects changes to direct or pleiotropic regulators.  174 
Likewise, there may be sequence variation among AmpC enzymes, affecting 175 
substrate specificity,24 and the genetic lesions causing inactivation of OprD are 176 
extremely variable.25   Such variations does not however negate the fact that the 177 
great majority of P. aeruginosa isolates (except those from cystic fibrosis, which are 178 
more complex) can readily be grouped by phenotype.16, 26-28  Isolates with 179 
anomalous, difficult-to-assign profiles comprised only 14 of the 851 studied here, 180 
forming the ‘mixed/uncertain’ group in Table 1. 181 
We conclude that the addition of relebactam gave a generalised potentiation 182 
of the carbapenem against P. aeruginosa and provides a potentially valuable option 183 
against those with ‘impermeability-type’ resistance to imipenem, regardless of their 184 
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AmpC and efflux status.  Its potential against ESBL-producing P. aeruginosa 185 
deserves further exploration, given their growing importance. 186 
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Table 1. Summary of MIC parameters according to resistance phenotype. 291 
Phenotype n Modal MIC (mg/L) MIC range (mg/L) Geometric mean MIC 
(mg/L) 
Antimicrobial Agent  CAR TZP CAZ IMP IMP/REL IMP IMP/REL IMP IMP/REL 
CAR-S, TZP-S, CAZ-S (wild-type)   
Imipenem S 669 64 4 2 1 0.25 0.06-4 0.06-2 0.77 0.27 
Imipenem N/S 37 64 4 2 16 1 8-32 0.5-4 11.9 0.93 
CAR-S, NS to either or both of TZP/CAZ (derepressed for AmpC) 
Imipenem S 13 128 32 8 1 0.25 0.5-2 0.125-0.5 1.0 0.33 
Imipenem N/S 9 128 32 16 16 1 8-32 0.5-2 13.7 0.93 
CAR-NS, proportionately raised TZP/CAZ (upregulated efflux) 
Imipenem S 73 256 16 4 0.5-1 0.25 0.25-4 0.125-2 0.99 0.35 
Imipenem N/S 29 >256 16-32 8 16 2 8-32 1-4 12.0 1.8 
ESBL-positive 2 Too few 8-16 2-4 11.3 2.8 
Carbapenemase-positive* 5 >256 32 16 32 32 32 ->256 16->256 64.0 55.7 
Uncertain/mixed           
Imipenem S 4 Too few 0.5-4 0.25-4 2 0.59 
Imipenem N/S 10 >256 256/>256 64 16 1-4 8-32 0.5-4 16 1.7 
Key: CAR, carbenicillin; CAZ, ceftazidime; IMP, imipenem; IMP/REL, imipenem with 4 mg/L relebactam; TZP, piperacillin/tazobactam; 292 
S, susceptible; NS, non-susceptible. *All five carbapenemase-positive isolates were MBL-positive: four have blaVIM and one blaNDM. 293 
Isolates with a MIC ≥128mg/L to carbenicillin and susceptibility to the other agents were categorised within the wild-type category and 294 
may include those with very minor up-regulations of efflux or acquired penicillinase. 295 
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Figure 1. Susceptibility of all P. aeruginosa tested against imipenem and imipenem with relebactam (n=851).  296 
 297 
The solid black line indicates the EUCAST breakpoint for imipenem and P. aeruginosa (S ≤4 mg/L; R >4 mg/L).  298 
* indicates the modal MIC distribution for each agent  299 
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